Monopar up as enrollment for oral mucositis drug trial begins

Monopar Therapeutics

05/10/2022 15:10

** Shares of Monopar Therapeutics Inc  MNPR.O  up 12.4%
at$1.91; their biggest daily pct rise in more than 3 months at
current levels
    ** Says it has started enrolling patients in late-stage part
of a trial to test its experimental drug, clonidine HCI
mucobuccal tablet, for preventing a type of cancer
treatment-related side effect  urn:newsml:reuters.com:*:nGNE1KHlX
    ** Also says it has completed enrollment for a part of its
mid-stage study and expanded the trial to include sites in
Germany and Poland
    ** Says interim results from analysis of mid-stage study
should be announced during Q1 2023
    ** Drug is being studied to prevent severe oral mucositis,
which causes tissue swelling and irritation in mouth, in
patients undergoing chemoradiotherapy for oropharyngeal cancer
    ** Including session gains, stock down 40.5% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))